- Home
- BIAF vs RVYL Comparison
BIAF vs RVYL Comparison
Compare BIAF & RVYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- RVYL
- Stock Information
- Founded
- BIAF 2014
- RVYL 2007
- Country
- BIAF United States
- RVYL United States
- Employees
- BIAF N/A
- RVYL N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RVYL Professional Services
- Sector
- BIAF Health Care
- RVYL Consumer Discretionary
- Exchange
- BIAF Nasdaq
- RVYL Nasdaq
- Market Cap
- BIAF 12.2M
- RVYL 10.3M
- IPO Year
- BIAF 2022
- RVYL N/A
- Fundamental
- Price
- BIAF $0.35
- RVYL $0.33
- Analyst Decision
- BIAF Hold
- RVYL Hold
- Analyst Count
- BIAF 1
- RVYL 1
- Target Price
- BIAF N/A
- RVYL N/A
- AVG Volume (30 Days)
- BIAF 12.3M
- RVYL 2.1M
- Earning Date
- BIAF 08-13-2025
- RVYL 08-12-2025
- Dividend Yield
- BIAF N/A
- RVYL N/A
- EPS Growth
- BIAF N/A
- RVYL N/A
- EPS
- BIAF N/A
- RVYL N/A
- Revenue
- BIAF $8,809,228.00
- RVYL $54,357,000.00
- Revenue This Year
- BIAF N/A
- RVYL $27.50
- Revenue Next Year
- BIAF $20.00
- RVYL $35.71
- P/E Ratio
- BIAF N/A
- RVYL N/A
- Revenue Growth
- BIAF 78.40
- RVYL N/A
- 52 Week Low
- BIAF $0.16
- RVYL $0.29
- 52 Week High
- BIAF $2.99
- RVYL $2.40
- Technical
- Relative Strength Index (RSI)
- BIAF 56.35
- RVYL 33.16
- Support Level
- BIAF $0.27
- RVYL $0.29
- Resistance Level
- BIAF $0.38
- RVYL $0.35
- Average True Range (ATR)
- BIAF 0.04
- RVYL 0.05
- MACD
- BIAF 0.01
- RVYL -0.03
- Stochastic Oscillator
- BIAF 73.43
- RVYL 8.02
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.